doi: 10.7326/0003-4819-90-5-802.
The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring
- PMID: 434689
- DOI: 10.7326/0003-4819-90-5-802
Item in Clipboard
The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring
Ann Intern Med.
1979 May.
Abstract
A proper choice of patient is critical in assuring both a satisfactory degree of lysis of the thrombus or embolus and a clinical course uncomplicated by serious hemorrhage. The best patients to treat are those who are seriously and acutely ill but without anatomic lesions that may bleed excessively. Thrombolytic agents can be administered by standard courses of therapy, and the monitoring of treatment with laboratory tests has been simplified and is concerned primarily with the documentation of a "lytic state."
Similar articles
-
Thrombolytic therapy. For pulmonary embolism and deep venous thrombosis.Postgrad Med. 1982 Apr;71(4):149-54, 158. doi: 10.1080/00325481.1982.11716048. Postgrad Med. 1982. PMID: 7071026
-
Current developments in thrombolytic therapy.Thromb Diath Haemorrh Suppl. 1973;56:201-10. Thromb Diath Haemorrh Suppl. 1973. PMID: 4617330 Review. No abstract available.
-
The current and future use of thrombolytic therapy.Annu Rev Pharmacol Toxicol. 1985;25:413-31. doi: 10.1146/annurev.pa.25.040185.002213. Annu Rev Pharmacol Toxicol. 1985. PMID: 3890708 Review. No abstract available.
-
Fibrinolytic guidelines in diabetes.Geriatrics. 1982 Apr;37(4):38-42, 46. Geriatrics. 1982. PMID: 7060947
-
Thrombolytic therapy.Br Med Bull. 1978 May;34(2):191-9. doi: 10.1093/oxfordjournals.bmb.a071491. Br Med Bull. 1978. PMID: 148935 Review. No abstract available.
Cited by
-
Adverse reactions to thrombolytic agents. Implications for coronary reperfusion following myocardial infarction.Med Toxicol Adverse Drug Exp. 1987 Jul-Aug;2(4):274-86. doi: 10.1007/BF03259869. Med Toxicol Adverse Drug Exp. 1987. PMID: 3306267 Review.
-
A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion.J Thromb Haemost. 2008 Jun;6(6):944-50. doi: 10.1111/j.1538-7836.2008.02969.x. Epub 2008 Apr 2. J Thromb Haemost. 2008. PMID: 18384651 Free PMC article. Clinical Trial.
-
Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator.J Clin Invest. 1987 Jun;79(6):1642-7. doi: 10.1172/JCI113001. J Clin Invest. 1987. PMID: 2953761 Free PMC article.
-
Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse.J Cell Biol. 1984 Mar;98(3):894-903. doi: 10.1083/jcb.98.3.894. J Cell Biol. 1984. PMID: 6365928 Free PMC article.
-
Physiological balance of haemostasis and bleeding.Drugs. 1987;33 Suppl 3:13-21. doi: 10.2165/00003495-198700333-00003. Drugs. 1987. PMID: 3315578 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
